Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Rating of "Buy" from Analysts

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) have been assigned a consensus rating of "Buy" from the twelve brokerages that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, ten have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $67.70.

Several brokerages recently weighed in on JANX. Leerink Partnrs raised shares of Janux Therapeutics to a "strong-buy" rating in a research report on Friday. HC Wainwright restated a "buy" rating and issued a $63.00 price target on shares of Janux Therapeutics in a research note on Thursday, November 7th. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Thursday, November 14th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $100.00 price objective on shares of Janux Therapeutics in a report on Thursday, November 7th. Finally, Scotiabank lowered their target price on shares of Janux Therapeutics from $47.00 to $42.00 and set a "sector perform" rating on the stock in a research note on Friday, August 9th.

Insider Buying and Selling

In related news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of Janux Therapeutics stock in a transaction on Friday, October 18th. The stock was acquired at an average price of $44.75 per share, for a total transaction of $53,700,000.00. Following the completion of the transaction, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. This represents a 14.78 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $42.00, for a total value of $4,551,330.00. Following the transaction, the insider now directly owns 3,162,851 shares in the company, valued at approximately $132,839,742. The trade was a 3.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 420,610 shares of company stock valued at $19,288,666. 29.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC boosted its holdings in Janux Therapeutics by 48.0% in the 3rd quarter. Virtu Financial LLC now owns 7,463 shares of the company's stock worth $339,000 after buying an additional 2,419 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Janux Therapeutics during the third quarter worth about $940,000. Geode Capital Management LLC grew its position in shares of Janux Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 662,594 shares of the company's stock worth $30,107,000 after purchasing an additional 38,490 shares in the last quarter. Barclays PLC raised its stake in Janux Therapeutics by 496.5% during the 3rd quarter. Barclays PLC now owns 174,061 shares of the company's stock valued at $7,907,000 after purchasing an additional 144,883 shares during the period. Finally, Y Intercept Hong Kong Ltd bought a new position in Janux Therapeutics in the 3rd quarter worth approximately $317,000. Institutional investors own 75.39% of the company's stock.

Janux Therapeutics Trading Down 1.7 %

Janux Therapeutics stock traded down $0.82 during mid-day trading on Tuesday, hitting $48.00. The company had a trading volume of 457,414 shares, compared to its average volume of 710,551. Janux Therapeutics has a 12 month low of $7.79 and a 12 month high of $65.60. The stock's 50 day moving average price is $50.05 and its two-hundred day moving average price is $45.83. The company has a market capitalization of $2.52 billion, a PE ratio of -41.03 and a beta of 3.52.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analysts' expectations of $1.50 million. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. Janux Therapeutics's revenue for the quarter was down 82.6% on a year-over-year basis. Equities research analysts anticipate that Janux Therapeutics will post -1.34 EPS for the current year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.